CAMP4 Therapeutics CorpCAMP
Price$3.84

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
35.0%projected annual EPS growth
As of 27 Aug 2026
Analyst Coverage
6analysts covering
As of 18 Aug 2026
FY Revenue (est.)
$6.3Mnext fiscal year
As of 18 Aug 2026
FY EPS (est.)
-$0.79next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly99.2MTarget: Sufficient to fund planned activities into 2028
CMP-002 Clinical Trial Initiation AnnuallyTarget: Initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026
Watch Items
  • CMP-002 Global Regulatory ApprovalsTrigger: Regulatory clearance of clinical trial applications (CTA/IND) in Australia and other global jurisdictionsAction: Initiate global Phase 1/2 clinical trial in SYNGAP1 patients
  • GSK Strategic Collaboration MilestonesTrigger: Identification and development of ASO drug candidates for neurodegenerative and kidney disease targetsAction: Recognize milestone-based payments up to $440 million
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.